Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 10, 2021 07:00 ET | Source: Rezolute, Inc.

Rezolute Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolute’s Oral PKI for Treatment of DME

REDWOOD CITY, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases...
August 03, 2021 07:00 ET | Source: Rezolute, Inc.

Rezolute to Participate in Upcoming Virtual Healthcare Conferences

REDWOOD CITY, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related...
June 28, 2021 07:00 ET | Source: Rezolute, Inc.

Rezolute Added to Russell Microcap® Index

REDWOOD CITY, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related...
May 27, 2021 07:00 ET | Source: Rezolute, Inc.

Rezolute to Participate in Upcoming Virtual Healthcare Conferences

REDWOOD CITY, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related to...
May 20, 2021 07:00 ET | Source: Rezolute, Inc.

Rezolute Expands Leadership Team with the Appointment of Davelyn Hood, MD as Director, Scientific and Patient Affairs

REDWOOD CITY, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated...
May 18, 2021 07:00 ET | Source: Rezolute, Inc.

Rezolute Appoints Leading Ophthalmology Expert, Quan Dong Nguyen, MD, MSc, FAAO, FARVO, to Scientific Advisory Board

REDWOOD CITY, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing novel therapies for diseases related to chronic glucose...
May 17, 2021 16:05 ET | Source: Rezolute, Inc.

Rezolute Reports Third Quarter Fiscal 2021 Financial Results and Highlights Recent Company Progress

REDWOOD CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated...
May 17, 2021 07:00 ET | Source: Rezolute, Inc.

Rezolute to Present at the Oppenheimer Rare and Orphan Disease Summit

REDWOOD CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing novel therapies for diseases caused by chronic glucose...
July 27, 2020 08:00 ET | Source: Rezolute, Inc.

Rezolute, Inc. Provides Updates in the Context of the COVID-19 Pandemic: Announces Resumption and US-Expansion of its Phase 2b Study in Congenital Hyperinsulinism

REDWOOD CITY, California, July 27, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today provided an update on the status of the Company’s clinical programs in...
June 15, 2020 08:30 ET | Source: Rezolute, Inc.

Rezolute Announces Publication of RZ402 Data in Diabetic Macular Edema (DME) in Investigative Ophthalmology & Visual Science

REDWOOD CITY, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OCTQB:RZLT), announced that the company’s abstract accepted to the virtual Association for...